Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06357533 · ClinicalTrials.gov registry record · Phase 3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
675
Enrollment target
20
Study locations

NCT06357533 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 675 participants, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06357533, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
675 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Datopotamab Deruxtecan
  • DRUG Rilvegostomig

Study Locations (20)

Florida

  • Research Site - Clermont
  • Research Site - Gainesville
  • Research Site - Miami Beach
  • Research Site - Orange City
  • Research Site - Orlando
  • Research Site - Orlando
  • Research Site - West Palm Beach

California

  • Research Site - Anaheim
  • Research Site - Beverly Hills
  • Research Site - Fountain Valley
  • Research Site - Newport Beach

Georgia

  • Research Site - Atlanta
  • Research Site - Atlanta
  • Research Site - Atlanta
  • Research Site - Atlanta

Arkansas

  • Research Site - Little Rock
  • Research Site - Springdale

Alaska

  • Research Site - Anchorage

Arizona

  • Research Site - Tucson

Illinois

  • Research Site - Hinsdale

Trial Details

FieldValue
Enrollment Target 675 participants
Start Date 2024-04-11
Est. Completion 2029-12-28
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06357533

The ClinicalTrials.gov registry entry for NCT06357533 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 675 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT06357533 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06357533 about?

NCT06357533 is a clinical study titled "Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations". The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (T...

What is the current status of trial NCT06357533?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2024-04-11. Estimated completion is 2029-12-28.

What conditions does trial NCT06357533 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT06357533?

The interventions under investigation include: Pembrolizumab (DRUG), Datopotamab Deruxtecan (DRUG), Rilvegostomig (DRUG).

Who is sponsoring clinical trial NCT06357533?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06357533 being conducted?

This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.